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Integrins and other families of cell adhesion receptors are responsible for platelet adhesion and aggregation, which are essential
steps for physiological haemostasis, as well as for the development of thrombosis. The modulation of platelet adhesive properties
is the result of a complex pattern of inside-out and outside-in signaling pathways, in which the members of the Rap family of
small GTPases are bidirectionally involved. This paper focuses on the regulation of the main Rap GTPase expressed in circulating
platelets, Rap1b, downstream of adhesion receptors, and summarizes the most recent achievements in the investigation of the
function of this protein as regulator of platelet adhesion and thrombus formation.
1.Introduction
The adhesion of circulating blood platelets to the suben-
dothelial matrix exposed upon vessel wall injury represents
the initial event of the haemostatic process required to limit
hemorrhage. Platelets express several membrane receptors
speciﬁc for all the major adhesive ligands of the vascular
extracellular matrix [1]. Among these, collagen is proba-
bly the most important subendothelial matrix component
involved in thrombus formation, and platelet adhesion to
collagen is associated with a complex pattern of activa-
tory signaling pathways. Integrin α2β1 and glycoprotein VI
(GPVI) are the two main platelet receptors for collagen and,
in the rheological conditions of low shear rates, typically
present in large veins and venules, are suﬃcient to mediate
ﬁrm platelet adhesion. At high shear rates, characteristic
of small arteries and stenotic vessels, platelets are unable
to eﬃciently interact to exposed collagen ﬁbers, and in
these conditions adhesion is preceded by platelet tethering
and rolling on the site of injury. This process is mediated
by the membrane GPIb-IX-V complex, a platelet-speciﬁc
receptor for the multimeric glycoprotein von Willebrand
factor (VWF). At high shear stress, circulating VWF rapidly
interacts with exposed collagen ﬁbers and undergoes a
conformational change that allows the interaction with the
GPIb-XI-V complex, decelerating platelets and favoring
the subsequent stable adhesion mediated by other platelet
receptors [2].
The interaction of platelet adhesion receptors with sub-
endothelial matrix components stimulates an intricate pat-
tern of signal transduction pathways, that trigger spreading,
secretion of soluble proaggregating molecules, thromboxane
A2 (TxA2) synthesis and release, and phosphatydilserine
exposure. These events recruit and activate additional circu-
lating platelets to initiate a process of cell aggregation, that
generates a rapidly growing thrombus at the site of damaged
vessel wall.
The stability of platelet adhesion and of the subsequent
thrombus formation is reinforced by autocrine stimulation
by the released soluble agonists, in particular ADP and
TxA2, and by thrombin produced through the coagulation
cascade. These agonists stimulate speciﬁc G-protein-coupled
receptors(GPCRs)expressedonplateletsurfaceandtypically
lead to the activation of phospholipase C (PLC) β isoforms,
that release diacylglycerol (DAG) and inositol trisphosphate
(IP3). IP3 mediates Ca2+ release from intracellular stores,
whereas DAG stimulates several eﬀectors containing the
DAG-regulated C1 domain, such as classical and novel pro-
tein kinase C isoforms [3]. Concomitantly, other signaling
molecules, including phosphatidylinositol 3 kinases (PI3Ks),2 Journal of Signal Transduction
protein tyrosine and serine/threonin kinases, and Ras-like
small GTPases, are activated and contribute to promote full
platelet activation. These events eventually promote platelet
aggregation and thrombus formation, which are supported
by the stimulation of integrin αIIbβ3, that is converted into
a high-aﬃnity state for ﬁbrinogen, whose binding mediates
interaction of adjacent cells promoting thrombus growth
[2, 4, 5].
Severalsignalingpathwaysevokeduponplateletadhesion
require the intervention of one or more Ras-like small
GTPases, that operate as molecular switches by cycling
between an inactive state bound to GDP and an active state
boundtoGTPthroughtheactionofspeciﬁcguaninenucleo-
tide exchange factors (GEFs) and GTPase-activating proteins
(GAPs)[6]. Plateletsexpress severalRas-like GTPase,includ-
ing Ras [7, 8], Ral [9], Rho [10], Rac [9] and, Cdc42 [11],
but are particularly rich of members of the Rap subfamily of
GTPases [12]. This paper will focus on platelet Rap GTPases
to highlight recent insights into the mechanism of activation
and recruitment upon stimulation of the major platelet
adhesion receptors.
2.RapGTPasesinPlatelets
It is now well established that Rap GTPases are involved in
several cell functions, including growth, proliferation, cell-
cell contact, and adhesion [13]. The Rap family consists
of ﬁve members: two Rap1 proteins (Rap1a and Rap1b)
that share 90% sequence homology and three Rap2 proteins
(Rap2a, Rap2b, and Rap2c) which are about 70% homolo-
gous to Rap1 [14–16]. An important diﬀerence between the
twosubfamiliesisthatRap2proteinstypicallydisplayalower
sensitivity to GAPs, promoting a prolonged Rap2 signaling
compared to that of Rap1. Although regulated by the same
set of GEFs and GAPs, Rap1 and Rap2 can be involved
in distinct processes, as shown in cell types diﬀerent from
platelets [17, 18], suggesting that they may operate through
diﬀerent eﬀectors. The biochemical basis of these diﬀerent
eﬀects has not been thoroughly investigated; however it
might also be related to the diﬀerences in posttranslational
modiﬁcations and subcellular localization of Rap1 and Rap2
isoforms [19].
Rap1b is the most abundant GTPase in platelets and
represents up to the 0.1% of total proteins, but platelets
also contain Rap2b, which, however, is about ten times less
abundant than Rap1b. Very low levels of Rap1a and Rap2a
have been detected in platelets, whereas Rap2c is not present
[12, 16, 20]. Probably because of these diﬀerent levels of
expression, only a limited number of studies have addressed
the biochemistry and function of Rap2b in platelets [19, 21–
24], while the majority of the investigations have focused on
Rap1b.
In platelets, the most abundant and functionally relevant
RapGEF is certainly the Ca2+- and DAG-regulated CalDAG-
GEFI, which represents the key regulator of Rap GTPases
activation downstream of PLC activation [25–28]. The
expression of low levels of other Rap1GEFs, as PDZ-GEF
and CalDAG-GEFIII, has also been reported, but in some
cases their presence remains controversial [29, 30]. The
only GAP speciﬁc for Rap GTPases identiﬁed in platelets is
Rap1GAP2, whereas Rap1GAP1, SPA-1, and E6TP1 have not
been found [29]. It has been shown that Rap1GAP2 is able
to associate with 14-3-3 and to modulate cell adhesion when
overexpressed in HeLa cells [31]; however the importance of
this regulator in platelet function is still unknown.
3. Rap GTPasesas Regulators of
PlateletIntegrinsandIntegrin-Mediated
Functions: Insights from Rap1b and
CalDAG-GEFIKnockout Mice
The role of Rap GTPases, and in particular of Rap1, in the
regulation of cell adhesion is well documented by a number
of observations in diﬀerent cell types [32–35]. Rap GTPases
participate to the conversion of integrins into a high-aﬃnity
state for their ligands, that in turn allows cells to interact, in
a controlled fashion, with other cells and with extracellular
matrix components. The ability of integrins to bind their
ligands is regulated by inside-out signaling pathways that
originate inside the cell and are then transmitted to the
extracellular ligand-binding domain of the receptor [36].
Integrin-mediated platelet functions include adhesion,
aggregation, and thrombus formation, and thus it appears
reasonable for Rap1b to be involved in these responses.
In this context, important information has been collected
upon the generation of the genetically modiﬁed mice that
do not express either Rap1b, or the main Rap1GEF present
in platelets, CalDAG-GEFI. Rap1b knockout mice display a
prolonged tail bleeding time and a marked protection from
platelet-dependent arterial thrombosis, demonstrating an
essential role of this GTPase in both haemostasis and throm-
bosis [37]. The importance of Rap1b activation in throm-
bus formation is also conﬁrmed by analysis of CalDAG-
GEFI knockout mice. Although the clotting parameters
are normal, CalDAG-GEFI knockout mice display strong
defects in haemostasis assessed by bleeding tail analysis
[26]. In addition, platelets in whole blood collected from
CalDAG-GEFI knockout mice fail to form thrombi when
perfused over a ﬁbrillar collagen surface both at low and
high shear rates [26, 38]. Moreover, the lack of CalDAG-
GEFI is also associated with defective in vivo thrombosis,
that is virtually abolished in arteries and strongly reduced
in venules [38]. These alterations of the haemostatic and
thrombotic functions of platelets, which are driven by both
cell-matrix and cell-cell adhesion, are indicative of a role
for Rap1b in the regulation on platelet integrin function.
Platelets express at least ﬁve diﬀerent integrins (αIIbβ3, α2β1,
α5β1, α6β1,a n dαvβ3) and in particular integrins αIIbβ3
and α2β1 play a predominant role in platelet adhesion
and activation [2]. However, integrins α5β1 and α6β1 are
required to mediate shear-resistant adhesion [39], whereas
the function of integrin αvβ3 is less understood.
An u m b e ro f“ ex vivo” studies on human and murine
plateletshavedemonstratedthatRap1bplaysacriticalrolein
the regulation of integrin αIIbβ3 aﬃnity state and, therefore,
controls platelet aggregation induced by soluble agonistsJournal of Signal Transduction 3
[26, 27, 37, 40]. Important information on the mechanism
of inside-out integrin activation has been collected using
transfected cell lines to reconstitute this signaling pathway.
These studies indicate that integrin signaling involves the
interaction of the head domain of the cytoskeletal protein
talin with speciﬁc sites of integrin β-tail and with the plasma
membrane [41, 42]. Talin can synergize with kindlin-1 and
-2 to mediate integrin αIIbβ3 conversion into the active state;
however, the overexpression of kindlin alone is not suﬃcient
to promote integrin activation [43]. In talin- and integrin
αIIbβ3-expressing CHO cells, the coexpression of PKC at lev-
els comparable to those present in platelets induces a strong
responsiveness to PMA exposure, and the overexpression of
a constitutive active form of Rap1a bypasses the requirement
of PKC, indicating that, in this model, Rap1 lies downstream
of PKC [44]. Among diﬀerent potential Rap1 eﬀectors,
RIAM (Rap1-interacting adaptor molecule) was shown to
be involved in integrin regulation, and its overexpression in
cell lines bypasses the requirement of Rap1. Moreover, RIAM
knockdown suppresses Rap1-mediated integrin activation,
as well as the association between talin and integrin β-
tail [45, 46]. However, the importance of RIAM in platelet
physiology and integrin αIIbβ3-mediated platelet aggregation
stillneedstobedeterminedandwillrequirethedevelopment
of RIAM knockout mouse models.
Further support to the hypothesis that Rap1b regulates
integrin aﬃnity was provided by the analysis of Rap1b and
CalDAG-GEFI knockout mice. Generally, the lack of Rap1b
orCalDAG-GEFIiscoupledtoasubstantialdefectinintegrin
αIIbβ3 activation and platelet aggregation. Rap1b-deﬁcient
platelets display a reduced aggregation in response to a wide
rangeofconcentrationsofagonists,asADPandepinephrine,
and to low doses of collagen, thrombin receptor-speciﬁc
agonist AYPGKF, and Ca2+ ionophore [37]. The lack of
CalDAG-GEFI is associated with a more severe reduction
of platelet aggregation caused by the same set of agonists,
whereasthe DAG analogue PMA and high doses of thrombin
induce a comparable extent of platelet aggregation in wild-
type and CalDAG-GEFI-deﬁcient platelets. The CalDAG-
GEFI-independent pathway leading to platelet aggregation
requires PKC activation, subsequent granule release, and
P2Y12 stimulation by secreted ADP [26, 28, 47].
Similarly to integrin αIIbβ3, also integrin α2β1 is present
on the platelet surface in at least two diﬀerent aﬃnity
states for its ligands, and conversion into the high-aﬃnity
state facilitates collagen-mediated platelet activation [48–
50]. In this context, it has been recently shown that, under
certain conditions, Rap1b expression is required to allow a
properintegrinα2β1 activation.Indeed,plateletsfromRap1b
knockout mice show defective integrin α2β1 activation upon
stimulation of the collagen receptor GPVI, but not upon
stimulation of thrombin or ADP receptors. However, the
extent of adhesion to collagen via integrin α2β1 is normal
in platelets from Rap1b knockout mice, suggesting that
adhesion to collagen under static conditions does not involve
Rap1b-dependent stimulation of integrin α2β1 [51].
Interestingly,incontrasttowhatwasobservedforRap1b-
deﬁcient platelets, platelets from CalDAG-GEFI knockout
mice display a reduced ability to adhere to immobilized col-
lagen under static conditions, when compared to wild-type
cells [27]. Moreover, also the ex vivo analysis of thrombus
formation on immobilized collagen under ﬂow has revealed
a reduced area coverage and thrombus growth in CalDAG-
GEFI knockout platelets. Interestingly, the addition of ADP
and TxA2 increases the adhesion of CalDAG-GEFI knockout
platelets to a collagen surface at low shear rates, without
restoring thrombus growth [38]. In addition to the key
role played in platelet adhesion to collagen, the expression
of CalDAG-GEFI is also required for an eﬃcient platelet
interaction with other β1 integrin ligands as laminin and
ﬁbronectin [52].
The observed diﬀerences between Rap1b and CalDAG-
GEFI knockout mice, which are particularly evident in terms
of phenotype severity, may be related to possible additional
functions of CalDAG-GEFI, independent of Rap1b activa-
tion, that can be required for eﬃcient integrin-mediated
adhesion. Moreover, in Rap1b knockout platelets Rap1a or
Rap2b could partially compensate the lack of Rap1b. Indeed,
although expressed at lower level Rap1a can be activated
by platelet stimulation in Rap1b knockout platelets [51]. By
contrast, since CalDAG-GEFI also stimulates Rap2b activity
in platelets [53], this isoform cannot compensate the lack
of Rap1b, and this may explain the more severe phenotype
of CalDAG-GEFI knockout mice. However, it should also
be considered that some discrepancy in the results obtained
from CalDAG-GEFI and Rap1b knockout mice simply
reﬂects the diﬀerent experimental conditions adopted.
4. Rap1b ActivationDownstream of
PlateletAdhesion Receptors
An increasing number of observations indicate that Rap
GTPases and adhesive receptors are connected in a bidirec-
tional fashion. As described above, a major role for Rap
GTPases is the regulation of integrin aﬃnity for the speciﬁc
ligands. In this context Rap1b activation is triggered by
stimulation of many GPCRs in platelets and participates to
the organization of the signaling pathway for integrin inside-
out activation. However, in the last years, an increasing
number of studies have proved the involvement of Rap1b
alsoinintegrinoutside-insignalingandhavedocumentedits
activation downstream of many platelet adhesive receptors.
4.1. Integrin α2β1-Mediated Rap1b Activation. Integrin α2β1
is a collagen receptor important for a proper hemostasis in
humans, as documented by the observation that mutations
of this receptor are associated with bleeding disorders and
reduced platelet responses to collagen [54, 55]. Integrin
α2β1 is a critical platelet adhesion receptor, that interacts
with collagen, by recognizing hexapeptidic sequences, such
as GFOGER, GLOGER, GASGER, GROGER, and GLOGEN
[56–58], but it also binds tenascin [59],andmediates platelet
adhesion to the small proteoglycan decorin [60].
Platelet adhesion via integrin α2β1 directly stimulates
Rap1b activation, without the need for further autocrine
stimulation by secreted ADP or released thromboxane4 Journal of Signal Transduction
A2 [27]. Experiments performed with platelets from genet-
ically modiﬁed mice have shown that CalDAG-GEFI is the
only GEF required for Rap1b stimulation downstream of
integrin α2β1 [27]. The dissection of the signaling pathway
involved indicates that PLCγ2 expression and activation
are mandatory for integrin α2β1-triggered Rap1b activation.
Interestingly, recruitment of platelet integrin α2β1 mediates
the activation of PLCγ2 by two redundant mechanisms: a
classical Src-mediated phosphorylation of PLCγ2 itself and a
phosphorylation-independent mechanism involving the Rac
GTPase [61]. These observations indicate the existence of
important crosstalk between Rac1 and Rap1b GTPases in the
control of platelet adhesion and activation, with Rac1 being
potentially upstream of Rap1b. As it will be discussed later,
the existence of a crosstalk between Rap and Rac has been
recently conﬁrmed also downstream of GPVI [53].
Further analysis of CalDAG-GEFI and PLCγ2 knockout
mice demonstrated that the lack of Rap1b activation is
accompanied by a signiﬁcant inhibition of integrin αIIbβ3
conversionintothehigh-aﬃnitybindingstateforﬁbrinogen,
demonstrating that Rap1b activation plays a key role in
the crosstalk between integrins and regulates integrin α2β1-
mediated platelet aggregation [27, 61]. More recently, it
has been demonstrated that maximal Rap1b activation
induced by integrin α2β1 downstream of PLCγ2r e q u i r e s
the contribution of an additional Ca2+-dependent signaling
pathway involving the focal adhesion kinase Pyk2 and the
subsequent stimulation of PI3Kβ. In fact, the lack or the
impaired activation of Pyk2 and PI3Kβ causes a defective
Rap1b activation triggered by integrin α2β1 engagement
[62]. These ﬁndings outline that, as previously observed in
platelets stimulated with ADP or other soluble agonists [63–
65], also in integrin α2β1 outside-in signaling Rap1b activity
is regulated by PI3K. Since virtually no residual Rap1b
activity is detected in CalDAG-GEFI-deﬁcient platelets, this
observation points to a contribution of PI3K activity in the
regulation of CalDAG-GEFI, but the molecular mechanism
for this process is still to be deﬁned.
4.2. GPVI-Mediated Rap Activation. GPVI is membrane gly-
coprotein speciﬁcally expressed in platelets, functionally
associatedwiththeITAM-containingtransmembraneadapt-
er protein FcR γ-chain [66, 67]. It is well documented that
plateletGPVIisresponsiblefortheﬁrstsetofsignalsinduced
by platelet interaction with collagen and that it strongly
cooperates with integrin α2β1 to mediate full collagen-
induced response [50, 68]. The GPVI-FcR γ-chain complex
initiates a tyrosine-kinase-based signaling cascade which
involves Src and Syk kinases, the adaptor proteins LAT and
SLP76, and leads to phosphorylation and stimulation of
PLCγ2[ 69]. Mouse or human platelets lacking GPVI–FcR γ-
chain display severe defects in collagen-induced activation,
integrin αIIbβ3 regulation and platelet aggregation [70–76].
As part of the signaling pathways for collagen-induced
platelet activation, GPVI stimulation triggers Rap1b activa-
tion. This process, however, is at least partially dependent
on ADP secretion and the subsequent stimulation of P2Y12
receptor, both in human and murine platelets [24, 65, 77].
Nevertheless, the existence of a direct, P2Y12-independent
pathway of GPVI-mediated Rap1b activation has been
conﬁrmedbytheanalysisofaggregationofplateletscollected
from wild-type and Rap1b knockout mice, performed in
the presence of ADP receptors antagonists. These experi-
ments show that the lack of Rap1b is associated with a
reduced ADP-independent, GPVI-mediated platelet aggre-
gation, demonstrating that this GTPase is required for an
eﬃcient GPVI signaling [78]. Interestingly, direct Rap1b-
activation-mediated downstream of GPVI depends on the
activity of PI3K, and it has been demonstrated that the
contributionofboththeαandβ isoformsofPI3Kisrequired
[65, 77, 78].
As for the other platelet collagen receptor, integrin α2β1,
CalDAG-GEFI is a speciﬁc regulator of Rap1b activation also
downstream of GPVI [28, 53]. In addition, a number of
GPVI-dependent responses have been found to be impaired
in CalDAG-GEFI-deﬁcient platelets. Some of these, such
as integrin αIIbβ3 activation, and platelet aggregation are
consistent with the well-documented role for Rap1b, and
other defects, such as the reduction of ERK signaling leading
to a decreased TxA2 synthesis, or the impaired granule
secretion, point to possible novel implication forthisGTPase
in platelet function [28, 53, 79].
The GPVI-mediated signaling pathway leading to Rap1b
activation involves the small GTPase Rac1 [53]. The obser-
vation that Rac1 is involved in PLCγ2-dependent stimula-
tion of Rap1b downstream of integrin α2β1[61]h a sb e e n
extended in a recent work by Stefanini and coauthors
showing that the two GTPases exert a mutual inﬂuence also
downstream of GPVI. Indeed, Rap1b signaling sustains Rac1
activation, and, in turn, Rac1 provides a feedback regulation
of Rap1 through CalDAG-GEFI and P2Y12.
Interestingly, the ability of GPVI-FcR γ-chain complex
to stimulate Rap1b has been directly compared to the
stimulation of the closely related Rap2b [24]. It has been
reported that GPVI ligation results in a time-dependent
Rap2b activation, that is not inﬂuenced by platelet aggre-
gation (i.e., integrin αIIbβ3-mediated ﬁbrinogen binding)
and actin cytoskeleton remodelling. Diﬀerently to what was
observed for Rap1b, secreted ADP plays only a negligible
role in Rap2b activation triggered by GPVI, whereas Ca2+
mobilization and PKC activation are both required. Another
remarkable diﬀerence between activation of Rap1b and
Rap2b downstream of GPVI is that Rap2b stimulation is
largely independent from PI3K activity. However, it is
important to note that PI3K inhibitors suppress thrombin-
induced Rap2b activation [24]. Rap1 and Rap2 are therefore
diﬀerently regulated by PI3K, depending on the nature of the
stimulus. Recently, it has been shown that Rap2b activation
depends on CalDAG-GEFI and P2Y12 signaling, similarly to
what was already demonstrated for Rap1b [53]. According
to the lower sensitivity to GAPs, Rap2b displays a higher
baseline activation that is also a more sustained in time,
compared to that of Rap1b [53, 80]. Unfortunately, Rap2b
knockout mice have not been generated yet. Therefore, our
current information on the contribution of Rap2b to platelet
adhesion is still really limited.Journal of Signal Transduction 5
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Figure 1: Schematic diagram of the main pathways regulating Rap1b activation during platelet adhesion. The ﬁgure summarizes the major
players involved in Rap1b activation mediated by platelet adhesion receptors. Downstream of integrin α2β1,P L C γ2 plays a critical role for
Rap1b activation, which, however, requires also the Pyk2-mediated stimulation of PI3Kβ. Rap1 stimulates inside-out activation on integrin
αIIbβ3 and thus it is a central player in the crosstalk between these two integrin receptors. The collagen receptor GPVI stimulates Rap1b
both directly, through PI3Kα and β, and indirectly through the autocrine stimulation of the P2Y12 receptor by secreted ADP. Moreover,
activated Rap1b facilitates platelet granule secretion and ADP release. Rap1b-mediated inside-out activation of integrin αIIbβ3 involves the
Rap1 eﬀector RIAM and the cytoskeletal proteins talin and kindlin. In turn, integrin αIIbβ3 binding to ﬁbrinogen stimulates an outside-in
signaling able to promote Rap1b activation, which is an essential step for platelet spreading on ﬁbrinogen.
4.3. Rap1b Activation Mediated by Integrin αIIbβ3 Outside-In
Signaling. Integrin αIIbβ3 (also known as GPIIb/IIIa) is the
most abundant platelet membrane receptor and is responsi-
ble of the binding of platelets to soluble ﬁbrinogen, a process
that mediates platelet aggregation [2]. As introduced before,
integrin αIIbβ3 undergoes a conformational change upon
platelet activation, that increases the receptor aﬃnity for ﬁb-
rinogen. This inside-out activation of the integrin function
involves Rap1b stimulation and its association with RIAM,
talin and other signaling and cytoskeletal proteins, such as
vinculin and kindlin [2, 44, 46]. However, in addition to
the key role in platelet aggregation, integrin αIIbβ3 is also
able to mediate platelet adhesion to immobilized ﬁbrinogen
and to other RGD-containing ligands, including VWF [81],
vitronectin [82], ﬁbronectin [83], and thrombospondin
[84]. Integrin αIIbβ3 interaction with its ligands initiates
an outside-in signaling pathway, that contributes to the
regulation of the later phases of platelet activation and is
required for ﬁrm platelet adhesion and spreading on extra-
cellular matrices [85–87] ,ﬁ b r i nc l o tr e t r a c t i o n[ 88], platelet
procoagulant activity, and microparticle release [89, 90].
The ﬁrst evidence for the involvement of Rap1b in inte-
grin αIIbβ3 outside-in signaling was obtained from studies
with thrombin-stimulated platelets in the presence of inte-
grin antagonists, including the peptide GRGDS, that prevent
ﬁbrinogenbinding andplateletaggregation.Inthiscontextit
wasinitiallyshownthatsustainedRap1bactivationmediated
by thrombin requires the interaction between integrin αIIbβ3
and ﬁbrinogen, as it was inhibited by the RGDS peptide [23].
The activation of Rap1b by integrin αIIbβ3 has been
conﬁrmed by the direct observation that platelet adhesion
to immobilized ﬁbrinogen stimulates the accumulation of
GTP-bound Rap1b [61]. Integrin αIIbβ3-mediated Rap1b
activation is regulated by multiple intracellular eﬀectors,
including Src kinases, PKC, and cytosolic Ca2+.M o r e o v e r ,
Rap1b-deﬁcient platelets display a reduced spreading on
ﬁbrinogen compared with wild-type controls, whereas clot
retraction is abolished, indicating that stimulation of Rap1b
is important for integrin αIIbβ3-mediated platelet responses
[37, 79].
4.4. GPIb-IX-V and VWF in Rap1b Activation. The GPIb-
IX-V receptor complex, which contains four transmembrane
proteins, GPIbα,G P I b β, GPIX, and GPV, mediates platelet
binding to VWF in a shear-dependent fashion. The VWF-
GPIb-IX-V interaction is required to slow down circulating
platelets on the site of injury and is strongly involved in
the regulation of integrin αIIbβ3 and in the formation of
arterial thrombi [91]. The adhesive function of GPIb-IX-V
is coupled to the generation of intracellular signals that
support platelet activation mainly through the phospho-
rylation of the ITAM-bearing FcγIIA receptor, which is6 Journal of Signal Transduction
physicallyassociatedwithit[92].Moreover,FcγIIAreceptor-
independent signal transduction pathways occurring down-
stream of GPIb-IX-V and leading to protein phosphory-
lation, calcium oscillation, and integrin αIIbβ3 activation
have been identiﬁed [93]. GPIb-IX-V ligation triggers the
subsequent activation of integrin αIIbβ3 that mediates ﬁrm
platelet adhesion and initiates thrombus formation.
Despite the relevance of the initial platelet adhesion
through GPIb-IX-V at the site of arterial injury for the whole
process of thrombus formation, the information about the
ability of this adhesion receptor to trigger Rap GTPases ac-
tivation is extremely limited. It has been shown that platelet
stimulation with VWF triggers the activation of both Rap1b
and Rap2b and promotes their association with the cell
cytoskeleton through a process involving the FcγIIA receptor
[23]. VWF-induced Rap2b translocation to the cytoskeleton,
inparticular,isdependentonintegrinαIIbβ3 asitisprevented
in the presence of anti-integrin αIIbβ3-speciﬁc antibodies, as
well as in patients aﬀected by Glanzmann’s thrombasthenia,
a genetic disorder associated with the lack of expression of
integrin αIIbβ3 [22].
Antibody-mediated clustering of FcγIIA receptor, that
inducesitstyrosinephosphorylationandmimicthesignaling
pathway triggered by VWF-mediated GPIb-IX-V stimula-
tion, is coupled to Rap1b activation in a fashion completely
dependent on secreted ADP [94]. Unfortunately, studies that
used transgenic mouse models to elucidate the role of Rap1b
in GPIb-IX-V-mediated platelet responses have not been
reported.
5. Conclusions
The great eﬀort devoted to understand the roles of Rap
GTPases in the regulation of platelet function produced a
huge amount of evidence demonstrating their critical role in
haemostasis and thrombosis. As schematically summarized
in Figure 1, the involvement of Rap GTPases in adhesion
dynamics is complex and bidirectional, as they are both acti-
vatedbyadhesivereceptorsandessentialfortheregulationof
the adhesive properties of integrins. The crucial implication
of Rap GTPases in the control of cell adhesion suggests that
the identiﬁcation of their eﬀectors may help to deﬁne novel
possible targets for eﬀective antiplatelet therapies for the
treatment of cardiovascular diseases.
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